Published October 2007
by Nova Science Pub Inc .
Written in English
|The Physical Object|
|Number of Pages||193|
Serum tumor markers in breast cancer / Franco Lumachi and Stefano M.M. Basso --Characterization of breast cancer subtypes by immunohistochemistry in a large retrospective study / J. Decock [and others] --New research communications on intraocular lymphoma markers / Min Zhou, Robert J. Ross and Chi-Chao Chan --Polymorphisms in energy homeostasis. Research progress in tumor markers. Ed. by Lilly Schafer and Emily Richter. Nova Science Publishers pages $ Hardcover RC Cancer cells produce substances known as markers, but so do normal cells. A tumor marker is anything present in or produced by cancer cells or other cells of the body in response to cancer or certain benign (noncancerous) conditions that provides information about a cancer, such as how aggressive it is, whether it can be treated with a targeted therapy, or whether it is responding to treatment.. Tumor markers have traditionally been proteins or other substances that. Clinical trials are currently in progress to assess if primary chemotherapy and interval debulking surgery should become the standard management of ovarian cancer rather than the traditional primary cytoreductive surgery. Women may present with peritoneal carcinomatosis, without either an obvious pelvic mass or an appropriate tumour marker profile.
A tumor marker is anything present in or produced by cancer cells or other cells of the body in response to cancer or certain benign (noncancerous) conditions that provides information about a cancer, such as how aggressive it is, whether it can be treated with a targeted therapy, or whether it . The tumor markers help both in early detection of the cancer and in monitoring the progress with the treatment. Tumor markers may be specific for a . Tumor markers are biochemical substances elaborated by tumor cells due to either the cause or effect of malignant process. produced by host in response to a tumor that can be used to differentiate. Serum level of marker reflects tumor burden. The level of the marker at the time of diagnosis may be used as a prognostic indicator for disease progression and patient survival. After successful initial treatment, such as surgery, the marker value should decrease. The rate of the decrease can be predicted by using the half life of the marker.
Despite extensive research, the role of the commonly employed tumour markers in the diagnosis of lung carcinoma is yet to be clarified. The utility of a new marker, CYFRA , in the preoperative. INTRODUCTION. The word spontaneous implies “without any apparent cause,” and regression is defined as a decrease in the size of the tumor or in the extent of cancer in the body according to the national cancer institute (NCI). Spontaneous regression occurs in most types of cancer and was recorded in the medical literature as early as . The effects of treatment, the presence, progress or risk for a disease can be checked by studying any alteration in the normal amount of a biomarker. A tumor marker, like a biomarker, is a naturally occurring substance in the body. An increased quantity of a tumor marker can show the presence of a cancer. Alpha-fetoprotein levels may be assessed by a blood test. Alpha-fetoprotein (AFP) is a tumor marker that is elevated in 60–70% of patients with hepatocellular carcinoma. Normally, levels of AFP are below 10 ng/ml, but marginal elevations (10–) are common in .